Processa Pharmaceuticals YTD Return
The PCSA YTD return is -25.00% with dividends reinvested through 07/10/2026. Investors often use YTD return to compare year-to-date performance across securities because current calendar year return information is important for tax planning.
This page shows PCSA YTD return, annualized return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.
| PCSA YTD Return Table | ||||||||||||||||||||||||||||||
PCSA YTD return is presented with the assumption of reinvestments of any dividends on ex-date. |
| YTD Return Benchmarks |
|
Compare PCSA YTD return (see YTD Return Meaning) versus benchmarks: YTD Return S&P YTD Return Dow YTD Return Nasdaq 100 YTD Return Russell 2000 YTD Return Gold YTD Return 10 Year Treasury YTD Return By Sector |
| PCSA Share Performance |
| PCSA YTD Return Chart | |||
Also see: PCSA Average Annual Return | |||
| About Processa Pharmaceuticals Inc |
| Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA's) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. The PCSA YTD return is shown above.
The YTD Return on the PCSA YTD return page and across the coverage universe of our site, is a measure of the total return for a given investment year-to-date for the current calendar year (up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely useful in the context of our country's tax system which taxes gains and income on a calendar year basis. Thus, researching Year-To-Date Returns is good practice for investors — whether PCSA YTD return or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the PCSA YTD return calculation (with any dividends reinvested as applicable), and to provide a coverage universe of many stocks and ETFs to be able to compare YTD returns. |
| PCSA Current Stock Quote |
Quotes delayed 20 minutes  Free PCSA Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Don't Forget Dividends in YTD Return! | |
|
| YTD Return Peers |
| Processa Pharmaceuticals (PCSA) is categorized under the Healthcare sector; to help you further research YTD return performance across stocks, below are some other companies in the same sector:
PCVX YTD Return PDCO YTD Return PDEX YTD Return PDSB YTD Return PEN YTD Return PEPG YTD Return PETV YTD Return PETX YTD Return PFE YTD Return PGEN YTD Return More Healthcare companies » |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.2%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.2%.
Video: Don't Forget Dividends in YTD Return!